GenSight Biologics S.A.
SIGHT.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | 107.2% | -50.9% | -51.1% | – |
| Cost of Goods Sold | €0 | -€0 | €0 | €0 |
| Gross Profit | €0 | €0 | €0 | €0 |
| % Margin | 100% | 236.8% | 100% | 100% |
| R&D Expenses | €0 | €0 | €0 | €0 |
| G&A Expenses | €0 | €0 | €0 | €0 |
| SG&A Expenses | €0 | €0 | €0 | €0 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | -€0 | €0 | €0 | €0 |
| Operating Expenses | €0 | €0 | €0 | €0 |
| Operating Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -602.4% | -2,343.8% | -1,078% | -533.1% |
| Other Income/Exp. Net | €0 | €0 | €0 | -€0 |
| Pre-Tax Income | -€0 | -€0 | -€0 | -€0 |
| Tax Expense | €0 | -€0 | €0 | €0 |
| Net Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -533.4% | -2,069.5% | -1,069.9% | -542.4% |
| EPS | -0.15 | -0.54 | -0.6 | -0.63 |
| % Growth | 72.2% | 10% | 4.8% | – |
| EPS Diluted | -0.15 | -0.54 | -0.6 | -0.63 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €0 | €0 |
| Interest Expense | €0 | €0 | €0 | €0 |
| Depreciation & Amortization | €0 | €0 | €0 | €0 |
| EBITDA | -€0 | -€0 | -€0 | -€0 |
| % Margin | -562.1% | -1,715.1% | -1,036.9% | -483.7% |